Skip to content
  • Why X-Chem
    • Our Difference
    • Discovery Philosophy
    • Chemomics
  • Insights & Results
    • Resource Center
      • All Resources
      • Case Studies
      • Press Releases
      • Scientific Posters
      • Scientific Publications
    • News
    • Target Classes
      • Protein-Protein Interactions
      • Targeted Protein Degradation Molecular Glues
      • Covalent Inhibitors
      • Kinases
      • GPCR Discovery
    • DEL Track Record
    • MedChem Track Record
  • Ways to Partner
    • Flexible Project Models
      • CandidateBuilder
      • HitBuilder
      • LeadBuilder
    • Fee for Service Packages
    • Platform Enablement
    • Strategic Collaborations
  • Our Technology
    • DEL Screening
    • Medicinal & Synthetic Chemistry
    • Research Products
    • Computational Sciences
  • About Us
    • Leadership
    • History
    • Careers
      • Why X-Chem
      • Job Opportunities
  • Contact Us
get in touch
  • Why X-Chem
    • Our Difference
    • Discovery Philosophy
    • Chemomics
  • Insights & Results
    • Resource Center
      • All Resources
      • Case Studies
      • Press Releases
      • Scientific Posters
      • Scientific Publications
    • News
    • Target Classes
      • Protein-Protein Interactions
      • Targeted Protein Degradation Molecular Glues
      • Covalent Inhibitors
      • Kinases
      • GPCR Discovery
    • DEL Track Record
    • MedChem Track Record
  • Ways to Partner
    • Flexible Project Models
      • CandidateBuilder
      • HitBuilder
      • LeadBuilder
    • Fee for Service Packages
    • Platform Enablement
    • Strategic Collaborations
  • Our Technology
    • DEL Screening
    • Medicinal & Synthetic Chemistry
    • Research Products
    • Computational Sciences
  • About Us
    • Leadership
    • History
    • Careers
      • Why X-Chem
      • Job Opportunities
  • Contact Us
get in touch

Press Releases

Press Releases

Press ReleasesAdminGG2025-08-22T15:40:43-04:00
  • All
  • 2016
  • 2017
  • 2018
  • 2019
  • 2020
  • 2021
  • 2022
  • 2023
  • 2024
  • 2025
  • 2025, Press Releases

    Cube Biotech and X‑Chem Partner to Enable DNA-encoded Library Screening of NativeMP™-stabilized Membrane Proteins

    MONHEIM, Germany and Waltham, Mass. , Aug. 21, 2025 — [...]

  • 2025, Press Releases

    X‑Chem Strengthens Executive Team with Strategic Finance and HR Appointments

    New leaders join X-Chem to support operational excellence and [...]

  • 2025, Press Releases

    Axxam and X‑Chem announce collaboration to broaden access to DNA-Encoded Library screening for early drug discovery

    Milan, Italy and Waltham, MA, USA, May 8, 2025 [...]

  • 2025, Press Releases

    X‑Chem Expands Strategic Collaboration with Orion Pharma to Accelerate Orion’s Early Drug Discovery from Hit to Candidate

    Waltham, MA, April 30, 2025 – X-Chem, a global leader [...]

  • 2024, Press Releases

    Tonix Pharmaceuticals Announces AI Collaboration with X‑Chem to Develop Broad-Spectrum Antivirals

    AI (Artificial Intelligence) and ML (Machine Learning) drug discovery [...]

  • 2024, Press Releases

    X‑Chem Announces Candidate Milestone

    WALTHAM, Mass.; Sept. 17, 2024 (Business Wire) – X-Chem, a [...]

  • 2024, Press Releases

    Evotec and X‑Chem Collaborate to Accelerate Early-Stage Drug Discovery

    WALTHAM, Mass.; Sept. 5, 2024 – Evotec SE (Frankfurt Stock Exchange: EVT, [...]

  • 2024, Press Releases

    Cancer Research Horizons appoints Therapeutic Innovation board to drive drug discovery strategy

    Carlos Garcia-Echeverria, Katharina Kreymborg and Karen Lackey become members [...]

  • 2024, Press Releases

    X‑Chem Strengthens Its Data-Driven Discovery Services With New CBO Appointment

    WALTHAM, Mass.; June 20, 2024 (Business Wire) – Small molecule [...]

  • 2024, Press Releases

    X‑Chem Adds Chief Technology Officer to Bolster Its Digital Drug Discovery Strategy

    WALTHAM, Mass.; April 2, 2024 (Business Wire) – X-Chem, the leading provider [...]

  • 2024, Press Releases

    Fibrolamellar Cancer Foundation: New research collaboration with X‑Chem

    FCF is pleased to announce the establishment of a research [...]

  • 2024, Press Releases

    X‑Chem Transitions Executives into New Roles, Appoints New Chief Executive Officer

    WALTHAM, Mass.; Jan. 4, 2024 (Business Wire) – X-Chem, [...]

  • 2023, Press Releases

    Rumi Scientific Announces Partnership with X‑Chem for Development of Lead Candidate in Huntington’s Disease

    NEW YORK, Dec. 05, 2023 (GLOBE NEWSWIRE) — Rumi Scientific [...]

  • 2023, Press Releases

    X‑Chem Announces Achievement of Collaboration Milestone

    WALTHAM, Mass.; Dec. 5, 2023 (Business Wire) — X-Chem, a global [...]

  • 2023, Press Releases

    X‑Chem and Structural Genomics Consortium Enter Into Collaboration to Unlock the Human Proteome and Promote Open Science

    WALTHAM, Mass.; Sept. 28, 2023 (Business Wire) – X-Chem, a global [...]

  • 2023, Press Releases

    X‑Chem and Kymera Expand Existing Partnership

    WALTHAM, Mass.; Jan. 31, 2023 – X-Chem, the leading provider [...]

  • 2023, Press Releases

    X‑Chem and Sironax Begin Neurodegenerative Disease Drug Discovery Research Partnership

    WALTHAM, Mass.; Jan. 5, 2023 (Business Wire) — X-Chem (X-Chem), the global [...]

  • 2022, Press Releases

    X‑Chem’s Noor Shaker Awarded for Achievements in AI for Drug Discovery

    WALTHAM, Mass.; March 30, 2022 (Business Wire) — X-Chem, the pioneer of [...]

  • 2022, Press Releases

    X‑Chem and Excelra’s GOSTAR Join Forces to Advance Drug Discovery for Challenging Targets

    LONDON and HYDERABAD, India; Feb. 9, 2022 – A new collaboration [...]

  • 2021, Press Releases

    X‑Chem Acquires Glamorous AI — Immediately Creating a Leader in DEL-Powered AI Solutions

    Combination Accelerates Outcomes in Early Drug Discovery WALTHAM, Mass.; [...]

  • 2021, Press Releases

    X‑Chem Acquires ComInnex

    Extending Functional and Global Leadership in Small Molecule Drug [...]

  • 2021, Press Releases

    BioDuro-Sundia and X‑Chem Enter Partnership to Launch DEL Services in China for the Discovery of New Small Molecule Drugs

    Shanghai, August 8 2022 – BioDuro-Sundia, an industry-leading drug discovery, [...]

  • 2021, Press Releases

    LEO Pharma and X‑Chem Enter Into Discovery Research Agreement

    Multi-target Collaboration to Focus on Identification of Novel Small [...]

  • 2021, Press Releases

    X‑Chem Announces OpenDEX DNA-Encoded Library Screening

    Flexible and Cost-Effective Solution for Screening Billions of Small [...]

  • 2021, Press Releases

    X‑Chem Enters into Multitarget Oncology Discovery Research Collaboration and License Agreement with Genentech

    Collaboration Includes Licensing of Preclinical Small Molecule Program  WALTHAM, [...]

  • 2021, Press Releases

    X‑Chem acquires IntelliSyn and sister company, AviSyn, to extend and streamline drug discovery service range

    Acquisition allows X-Chem to offer a more comprehensive, integrated, [...]

  • 2021, Press Releases

    Servier and X‑Chem Announce Drug Discovery Collaboration in Neurological Diseases

    Download PDF Paris and Waltham, Mass.; Jan. 6, [...]

  • 2021, Press Releases

    X‑Chem Announces Licensing of Second Drug Discovery Program to Otsuka

    Download PDF Waltham, Mass – January 4, 2021 [...]

  • 2020, Press Releases

    X‑Chem Announces Achievement of Milestone In Orexia Collaboration

    Download PDF Waltham, Mass – July 22, 2020 [...]

  • 2020, Press Releases

    Study Published in the Journal of Medicinal Chemistry Demonstrates the Power of Machine Learning to Unlock New Chemistry and Biology to Treat Disease

    Download PDF Study Published in the Journal of [...]

  • 2020, Press Releases

    GHO Capital Acquires X‑Chem, the Leading Provider of DNA-Encoded-Library-Mediated Drug Discovery Services

    Download PDF  Matt Clark named new Chief Executive [...]

  • 2020, Press Releases

    X‑Chem Announces Licensing of a Drug Discovery Program to Otsuka

    Download PDF Waltham, Mass – May 20, 2020 [...]

  • 2020, Press Releases

    ALK-Abelló and X‑Chem Announce Drug Discovery Collaboration

    WALTHAM, Mass. – February 5, 2019 – X-Chem, Inc. [...]

  • 2020, Press Releases

    ZebiAI Therapeutics, Inc. and X‑Chem Enter into Strategic Agreement to Enable Validation of Novel Therapeutic Targets and Acceleration of Drug Candidate Discovery

    Download PDF New venture capital-backed artificial intelligence company [...]

  • 2019, Press Releases

    Maruho and X‑Chem Announce Drug Discovery Collaboration

    Download PDF WALTHAM, Mass. – September 4, 2019 [...]

  • 2019, Press Releases

    X‑Chem and Vertex Expand Existing Partnership

    Download PDF – Expanded collaboration doubles scope of [...]

  • 2025, Press Releases

    X‑Chem Enters Strategic Collaboration with Bristol-Myers Squibb

    Download PDF WALTHAM, Mass. – December 18, 2018 [...]

  • 2018, Press Releases

    Almirall and X‑Chem Announce Dermatology-Focused Drug Discovery Collaboration

    Download PDF WALTHAM, Mass. – December 12, 2018 [...]

  • 2018, Press Releases

    X‑Chem Announces Licensing of 50th Drug Discovery Program

    Download PDF WALTHAM, Mass. – July 26, 2018 [...]

  • 2018, Press Releases

    X‑Chem spin-off X-Biotix Therapeutics Completes $7 million Series A Financing

    Download PDF WALTHAM, Mass. April 24, 2018 – [...]

  • 2018, Press Releases

    X‑Chem Appoints Christelle Huguet, Ph.D. as Chief Scientific Officer

    Download PDF – Additional Executive Leadership Appointment Announced: [...]

  • 2018, Press Releases

    X‑Chem Announces Licensing of Two Discovery Programs to AbbVie

    Download PDF – License grants AbbVie exclusive rights [...]

  • 2018, Press Releases

    X‑Chem Enters Expanded Global Drug Discovery and Technology Transfer Collaboration with AstraZeneca

    Download PDF – Latest contract extension stresses the value [...]

  • 2017, Press Releases

    X‑Chem Provides Year-End Update on Partnership Achievements

    Download PDF Announces 40th Drug Discovery License Nine [...]

  • 2017, Press Releases

    Otsuka and X‑Chem Enter into a Drug Discovery Research and License Collaboration

    Download PDF Otsuka Pharmaceutical Co., Ltd. (Otsuka) and [...]

  • 2017, Press Releases

    X‑Chem and Abilita Bio Announce a Joint Research Collaboration

    Download PDF – The research collaboration will combine [...]

  • 2017, Press Releases

    X‑Chem and Gilead Announce Drug Discovery Collaboration

    Download PDF – Agreement leverages X-Chem’s DEX™ DNA-Encoded [...]

  • 2017, Press Releases

    Consortium of X‑Chem, Harvard T.H. Chan School of Public Health and Other Leading Academic Institutions Wins Research Award from the Department of Defense

    Download PDF — Funding of $9.9 million by [...]

  • 2017, Press Releases

    X‑Chem further expands Collaboration with Bayer to Discover Novel Medicines

    Download PDF – Second expansion adds Bayer custom [...]

  • 2017, Press Releases

    X‑Chem and Vertex Enter into Multi-Target Genetic Disease Collaboration

    Download PDF – Agreement will enable discovery of small-molecule [...]

  • 2017, Press Releases

    X‑Chem Announces Publication in Nature

    Download PDF – Crystal Structure of PAR2 complexed with [...]

  • 2017, Press Releases

    X‑Chem and Ono Enter into Multi-Target Drug Discovery Collaboration

    Download PDF – Agreement marks X-Chem’s third drug discovery [...]

  • 2017, Press Releases

    X‑Chem Announces Strategic Collaboration with Astellas Pharma Across Multiple Therapeutic Areas

    Download PDF WALTHAM, Mass. – March 20 2017 [...]

  • 2017, Press Releases

    X‑Chem Expands Collaboration with Janssen in Inflammatory Diseases

    Download PDF — Event represents X-Chem’s fifth collaboration expansion [...]

  • 2016, Press Releases

    X‑Chem Marks the Spot for Bayer in Sweetened Drug Discovery Deal

    July 13 2016 | BIOWORLD TODAY | Bayer AG and [...]

North America
Europe

United States

X-Chem Global HQ
100 Beaver Street
Waltham, MA 02453
United States
Map

Canada

X-Chem Canada
4800 Rue Levy
Montreal, QC H4R 2P1
Canada
Map

Hungary

X-Chem Europe
Graphisoft Park (Building D)
1031 Budapest, Záhony u. 7.
Hungary
Map

Terms & Conditions

© 2025 X-Chem, Inc. • All Rights Reserved

Sign-up for Our Newsletter

Be first to see what’s next in drug discovery.

X-Chem may contact you with relevant updates. Unsubscribe anytime. See our Privacy Policy.

Terms & Conditions

© 2025 X-Chem, Inc. • All Rights Reserved

Page load link
  • Why X-Chem
    • Our Difference
    • Discovery Philosophy
    • Chemomics
  • Insights & Results
    • Resource Center
      • All Resources
      • Case Studies
      • Press Releases
      • Scientific Posters
      • Scientific Publications
    • News
    • Target Classes
      • Protein-Protein Interactions
      • Targeted Protein Degradation Molecular Glues
      • Covalent Inhibitors
      • Kinases
      • GPCR Discovery
    • DEL Track Record
    • MedChem Track Record
  • Ways to Partner
    • Flexible Project Models
      • CandidateBuilder
      • HitBuilder
      • LeadBuilder
    • Fee for Service Packages
    • Platform Enablement
    • Strategic Collaborations
  • Our Technology
    • DEL Screening
    • Medicinal & Synthetic Chemistry
    • Research Products
    • Computational Sciences
  • About Us
    • Leadership
    • History
    • Careers
      • Why X-Chem
      • Job Opportunities
  • Contact Us
P : +1 781.419.6900
Email Us
Manage Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
View preferences
{title} {title} {title}
Manage Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
View preferences
{title} {title} {title}
Go to Top